PubMed:20558148 / 857-1141 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"7581","span":{"begin":0,"end":11},"obj":"ChemicalEntity"},{"id":"7582","span":{"begin":20,"end":29},"obj":"DiseaseOrPhenotypicFeature"},{"id":"7583","span":{"begin":91,"end":114},"obj":"GeneOrGeneProduct"},{"id":"7584","span":{"begin":128,"end":134},"obj":"ChemicalEntity"},{"id":"7585","span":{"begin":166,"end":169},"obj":"ChemicalEntity"},{"id":"7586","span":{"begin":208,"end":221},"obj":"GeneOrGeneProduct"},{"id":"7587","span":{"begin":230,"end":250},"obj":"ChemicalEntity"},{"id":"7588","span":{"begin":252,"end":256},"obj":"ChemicalEntity"}],"attributes":[{"id":"A8","pred":"db_id","subj":"7581","obj":"MESH:D006220"},{"id":"A9","pred":"db_id","subj":"7582","obj":"MESH:D002375"},{"id":"A10","pred":"db_id","subj":"7583","obj":"NCBIGene:24408"},{"id":"A11","pred":"db_id","subj":"7584","obj":"MESH:D016291"},{"id":"A12","pred":"db_id","subj":"7585","obj":"MESH:C031231"},{"id":"A13","pred":"db_id","subj":"7586","obj":"NCBIGene:24408"},{"id":"A14","pred":"db_id","subj":"7587","obj":"MESH:D016202"},{"id":"A15","pred":"db_id","subj":"7588","obj":"MESH:D016202"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-sentences","denotations":[{"id":"T6","span":{"begin":0,"end":284},"obj":"Sentence"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T23","span":{"begin":12,"end":19},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":91,"end":100},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":101,"end":114},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":115,"end":126},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":136,"end":141},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":171,"end":176},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":208,"end":221},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":241,"end":250},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":252,"end":256},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":258,"end":263},"obj":"GeneOrGeneProduct"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T14","span":{"begin":91,"end":100},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":101,"end":114},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":208,"end":221},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":241,"end":250},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":252,"end":256},"obj":"GeneOrGeneProduct"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T3","span":{"begin":20,"end":29},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D002375"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T3","span":{"begin":91,"end":100},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":101,"end":114},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":208,"end":221},"obj":"GeneOrGeneProduct"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T3","span":{"begin":20,"end":29},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"D002375"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T3","span":{"begin":20,"end":29},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A3","pred":"#label","subj":"T3","obj":"D002375"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T10","span":{"begin":0,"end":11},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":91,"end":100},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":101,"end":105},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":128,"end":134},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":166,"end":169},"obj":"ChemicalEntity"},{"id":"T18","span":{"begin":208,"end":212},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":230,"end":250},"obj":"ChemicalEntity"},{"id":"T21","span":{"begin":252,"end":256},"obj":"ChemicalEntity"}],"attributes":[{"id":"A10","pred":"ID:","subj":"T10","obj":"D006220"},{"id":"A11","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_5613"},{"id":"A12","pred":"ID:","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_29987"},{"id":"A13","pred":"ID:","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_14321"},{"id":"A14","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A15","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D016291"},{"id":"A17","pred":"ID:","subj":"T17","obj":"ChemicalEntity"},{"id":"A18","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A19","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A20","pred":"ID:","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A21","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A22","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T21","span":{"begin":252,"end":256},"obj":"ChemicalEntity"},{"id":"T20","span":{"begin":230,"end":250},"obj":"ChemicalEntity"},{"id":"T18","span":{"begin":208,"end":212},"obj":"ChemicalEntity"},{"id":"T17","span":{"begin":166,"end":169},"obj":"ChemicalEntity"},{"id":"T16","span":{"begin":128,"end":134},"obj":"ChemicalEntity"},{"id":"T14","span":{"begin":101,"end":105},"obj":"ChemicalEntity"},{"id":"T12","span":{"begin":91,"end":100},"obj":"ChemicalEntity"},{"id":"T10","span":{"begin":0,"end":11},"obj":"ChemicalEntity"},{"id":"T4140","span":{"begin":208,"end":221},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":101,"end":114},"obj":"GeneOrGeneProduct"},{"id":"T77482","span":{"begin":91,"end":100},"obj":"GeneOrGeneProduct"},{"id":"T71239","span":{"begin":20,"end":29},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A22","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A21","pred":"ID:","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A20","pred":"ID:","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A19","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A18","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A17","pred":"ID:","subj":"T17","obj":"ChemicalEntity"},{"id":"A16","pred":"ID:","subj":"T16","obj":"D016291"},{"id":"A15","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_31882"},{"id":"A14","pred":"ID:","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_6121"},{"id":"A13","pred":"ID:","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_14321"},{"id":"A12","pred":"ID:","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_29987"},{"id":"A11","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_5613"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D006220"},{"id":"A51631","pred":"#label","subj":"T71239","obj":"D002375"}],"text":"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl)."}